<h1>Bal Pharma Ltd grants shareholders a grace period for comments regarding Postal Ballot Corrigendum</h1>
Bal Pharma Ltd has announced an opportunity for its members to submit comments and objections concerning the modifications made in the Corrigendum to its Postal Ballot Notice. The company extended this special window following observations received from the Stock Exchange related to the aforementioned document.
The intimation clarified that, to ensure transparency and provide a chance to shareholders who had previously exercised their voting rights, the company has set aside 48 hours from the date of publication for receiving comments or objections regarding the modifications introduced through the Corrigendum.
Members seeking to submit any observations regarding the changes in the Corrigendum are requested to do so within this 48-hour period. The provided contact methods include dedicated email addresses for the company and the scrutinizer.
The announcement also confirmed that members who cast their votes prior to the issuance of the Corrigendum have been given a facility to revise or modify those votes as per the specified procedure. This provision is intended to ensure that all stakeholders can place their comments, observations, or objections on record regarding the changes.
In addition to the opportunity for feedback, Bal Pharma confirmed that the remote e-voting facility will remain open until 5:00 P.M. (IST) on Saturday, August 08, 2026, as detailed in the Postal Ballot Notice and its Corrigendum.
BALPHARMA Stock Price Movement
Today, Bal Pharma Limited shares closed higher after post-market trading, edging up by 0.17% to settle at ₹87.9. During the session, the stock saw a traded volume of 7,965 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.